Welsh, Carson, Anderson & Stowe XII, L.P. sold 10,000,000 shares of INNV (indirect holdings)
Welsh, Carson, Anderson & Stowe XII, L.P. sold 10,000,000 indirectly-held shares of InnovAge Holding Corp. (INNV) on 2026-09-24. Filed jointly with WCAS CO-INVEST ASSOCIATES LLC (10% owner), Welsh, Carson, Anderson & Stowe XII Delaware, L.P. (10% owner), Welsh, Carson, Anderson & Stowe XII Delaware II, L.P. (10% owner), Welsh, Carson, Anderson & Stowe XII Cayman, L.P. (10% owner), WCAS XII Co-Investors LLC (10% owner), WCAS MANAGEMENT CORP (10% owner), WCAS - CO-INVEST HOLDCO, L.P. (10% owner), WCAS XII ASSOCIATES LLC (10% owner) and WCAS XII ASSOCIATES CAYMAN, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The filing reveals a substantial block sale by a major shareholder, which can influence short‑term price dynamics.
Market read
Insider sell of 10M shares may trigger short‑term bearish pressure on INNV.
What to watch
No disclosed price or reason; the insider may have liquidity needs unrelated to company outlook.
Background
SEC Form 4 provides a primary source disclosure of insider transactions.
Ticker impact
Form 4 filing shows WCAS sold 10,000,000 shares of InnovAge Holding Corp., reducing its stake but still holding 102,576,555 shares.
likely downward pressure as the market prices in the insider sell
10M shares represent a sizable block from a 10% owner; such sales often precede short‑term price weakness.
Market effects
May weigh on the biotech/healthcare sector if investors view insider selling as a red flag.
Limited to US markets where INNV trades.
Minimal global impact beyond sector sentiment.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- companyInnovAge Holding Corp.
Biotech firm listed on Nasdaq under ticker INNV.
- investment_firmWelsh, Carson, Anderson & Stowe XII, L.P.
Private equity firm acting as a 10% owner of INNV.